https://www.selleckchem.com/pr....oducts/sbi-0640756.h
Expanded hemodialysis (HDx) effectively removes large middle molecular uremic toxins (25 kDa) while still retaining albumin, potentially reducing their adverse effects. We compare the clinical laboratory parameters, hospitalization rates, and medication use in a cohort of patients switched from high-flux HD to HDx. This is a multicenter, observational cohort study of 81 adult patients, across 3 clinics, with end-stage kidney disease (ESKD) on chronic hemodialysis (HD). Patients received high-flux HD for at least 1 year and then
Like
Comment
Share
